Navigation Links
FZ60 monobloc hard & soft IOL

ProductsFZ60 monobloc hard & soft IOL
Company IOLTECH Laboratories (now part of Carl Zeiss Meditec, Inc.)
Item FZ60 monobloc hard & soft IOL
Features 
  • Advantages of two materials: PMMA and IOLTECH hydrophilic acrylic.
  • Good mechanical properties and biocompatibility.
  • Square edges to create a barrier to cell proliferation.
  • Optimal centration and stability of the optic.
Description FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technology warrantes no junction between the soft optic and the rigid haptics.
Info IOLTECH Laboratories (now part of Carl Zeiss Meditec, Inc.)
Customer Service: (33) 05 46 44 85 50

Related medicine products :

1. FLEXOR TUOHY-BORST Side-Arm Introducers ANSEL Modification with Radiopaque Band and AQ Hydrophilic Coating
2. Foldable Hydrophilic IOL with UV Absorber
3. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens
4. HAPTIBAG Hydrophilic Acrylic Lens
5. TRIPODE Hydrophilic Acrylic Lens
6. XL OCTO Hydrophilic Acrylic Lens
7. XL STABI Hydrophilic Acrylic Lens
8. STABIBAG Hydrophilic Acrylic Lens
9. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal)
10. Clo-Sur P.A.D. Nonwoven Hydrophilic Wound Dressing
11. Hydrophilic Personal Catheter-Pediatric
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Hologic, Inc.,(Nasdaq: HOLX ) announced today that ... that the pre-market application for,Adiana(R) Permanent Contraception for ... by a vote of 10 to 3., ... traditionally follows the,recommendations of its advisory panels. The ...
... now ensnaring,some of the nations leading retailers, a ... Target, Safeway, and Wild Oats of consumer fraud,for ... in federal courts in Seattle, Denver, and in,Minneapolis, ... class action,lawsuits against Aurora Dairy Corporation, based in ...
... Speaker Nancy Pelosi,issued the following statement on the report ... which found widespread use,of steroids and other illegal substances ... a troubling story of how many of our,children,s heroes ... our national,pastime by using steroids and other illegal substances., ...
... cite concerns that consumers wouldn,t use the cholesterol-lowering drug safely ... time in seven years, U.S. Food and Drug Administration advisers ... the cholesterol-lowering drug Mevacor available over the counter. , In ... advisers said Thursday that it would be too complicated for ...
... IRVING, Texas, Dec. 13 Allarae Healthcare,Inc. (Pink Sheets: ... with Intellect, Inc. to sell their entire product line ... broad range,of personal health testing kits, several already FDA ... kits are ready for market but have,not yet been ...
... Corporation,(Nasdaq: RGEN ) announced today that Dr. ... Board of Directors. Dr. Henry is a highly ... the,development of therapeutics for disorders affecting the Central ... an executive with Earl,s industry,knowledge and drug development ...
Cached Medicine News:Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 2Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 3Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 4Health News:Nation's Largest Retailers Accused of Organic Fraud 2Health News:FDA Advisers Reject Over-the-Counter Statin 2Health News:FDA Advisers Reject Over-the-Counter Statin 3Health News:FDA Advisers Reject Over-the-Counter Statin 4Health News:Allarae Healthcare Inc. Announces Signing of Distribution Agreement With Intellect Inc. 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 3
(Date:1/15/2014)... , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ... has fueled rapid growth of these markets. ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ... $2.92 per share, net to the seller in cash, ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4